Melodie Bonvalet
Overview
Explore the profile of Melodie Bonvalet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bredel D, Tihic E, Mouraud S, Danlos F, Susini S, Aglave M, et al.
J Exp Clin Cancer Res
. 2023 Dec;
42(1):333.
PMID: 38057799
Background: In addition to anti-PD(L)1, anti-CTLA-4 and anti-LAG-3, novel immune checkpoint proteins (ICP)-targeted antibodies have recently failed to demonstrate significant efficacy in clinical trials. In these trials, patients were enrolled...
2.
Miholjcic T, Halse H, Bonvalet M, Bigorgne A, Rouanne M, Dercle L, et al.
Eur J Cancer
. 2023 Jan;
181:166-178.
PMID: 36657325
Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer...
3.
Derosa L, Routy B, Thomas A, Iebba V, Zalcman G, Friard S, et al.
Nat Med
. 2022 Feb;
28(2):315-324.
PMID: 35115705
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila...
4.
Bonvalet M, Danlos F, Champiat S, Rouanne M, Marabelle A
Eur J Cancer
. 2022 Jan;
162:130-132.
PMID: 34983015
No abstract available.
5.
Dubuisson A, Fahrner J, Goubet A, Terrisse S, Voisin N, Bayard C, et al.
EMBO Mol Med
. 2020 Dec;
13(1):e12850.
PMID: 33372722
Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best...
6.
Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, et al.
Oncoimmunology
. 2020 Sep;
9(1):1774298.
PMID: 32934879
Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as...
7.
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al.
Eur Urol
. 2020 May;
78(2):195-206.
PMID: 32376136
Background: The development of immune checkpoint blockade (ICB) has revolutionized the clinical outcome of renal cell carcinoma (RCC). Nevertheless, improvement of durability and prediction of responses remain unmet medical needs....
8.
Luo G, Lin L, Jacob L, Bonvalet M, Ambati A, Plazzi G, et al.
PLoS One
. 2019 Mar;
14(3):e0214340.
PMID: 30921380
[This corrects the article DOI: 10.1371/journal.pone.0187305.].
9.
Luo G, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X, et al.
Proc Natl Acad Sci U S A
. 2018 Dec;
115(52):E12323-E12332.
PMID: 30541895
Type 1 narcolepsy (T1N) is caused by hypocretin/orexin (HCRT) neuronal loss. Association with the HLA DQB1*06:02/DQA1*01:02 (98% vs. 25%) heterodimer (DQ0602), T cell receptors (TCR) and other immune loci suggest...
10.
Luo G, Lin L, Jacob L, Bonvalet M, Ambati A, Plazzi G, et al.
PLoS One
. 2017 Dec;
12(12):e0187305.
PMID: 29220370
Background: A recent publication suggested molecular mimicry of a nucleoprotein (NP) sequence from A/Puerto Rico/8/1934 (PR8) strain, the backbone used in the construction of the reassortant strain X-179A that was...